To receive the accounts for the financial year ended 31 January 2021 together with the Directorsʼ Report and the Auditorʼs Report for that period
To elect Trevor Jones as a Director of the Company
To re-appoint Grant Thornton UK LLP as the Auditor of the Company
To authorise the Directors to set the remuneration of the Auditor of the Company
To authorise Directors to allot equity securities for cash in connection with the conditional firm placing, subscription and retail offer
To authorise Directors to allot shares and grant rights to subscribe for, or convert any security into, shares
To authorise Directors to allot equity securities for cash
Notes:
All resolutions passed at the AGM by way of poll
The total number of shares in issue at the close of proxy voting was 420,773,546
Attachments
Original document
Permalink
Disclaimer
e-Therapeutics plc published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 12:49:06 UTC.
e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.
E-THERAPEUTICS PLC 
